Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Idenix nets $165.9mm via FOPO

Executive Summary

Infectious disease-focused Idenix Pharmaceuticals Inc. has netted $165.9mm through the follow-on public offering of 22mm common shares at $8.00 each. The company will use a portion of the proceeds for ongoing development activities, including combination Phase IIb trials of IDX184 with IDX719 for hepatitis C, and proof-of-concept and Phase IIa studies of IDX19368 in combination with ribavirin, also for HCV.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies